Please assess the completion status of the following clinical trial:

Trial Title: The Effect of 90-day Oral Testosterone Therapy in Chinese Males With Type 2 Diabetes (T2DM)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is a Chinese male~* Subject is 45 to 75 years old~* Subject has T2DM with no change in type/dose of diabetic medication in the last 3 months~* Subject 's Haemoglobin level is between 13.5 - 18g/dl~* Subject's Haematocrit level is 40 - 54%~* Subject's Albumin level is between 3.5 - 5.0 g/dL~* Subject's Alanine transaminase (ALT) level is up to 36 U/L~* Subject's Aspartate transaminase (AST) level is \< 41 U/L~* Subject's Alkaline phosphatase (ALP) level is \< 130 U/L~* Subject's Creatinine (up to 60 years) level is between 0.57 - 1.36 mg/dL~* Subject's Creatinine (\> 60 years) level is between 0.68 - 1.48 mg/dL~* Subject's Sodium (13 to 65 years) level is between 136 - 145 mmol/L~* Subject's Sodium ( \> 65 years) level is between 132 - 146 mmol/L~* Subject's Potassium ( up to 59 years) level is between 3.3 - 5.1 mmol/L~* Subject's Potassium ( \> 59 years) level is between 3.7 - 5.4 mmol/L~* Subject's PSA (Prostate Specific Antigen) level is ≤ 4ug/L~* Subject's Total Testosterone level is between 8.4 - 28.7 nmol/L~* Satisfactory haematological or biochemical functions tests only - these tests should be carried out during the screening period prior to enrolment. Patient with mild laboratory abnormalities can be included at the discretion by the site/co-investigator, and after approval by Co-ordinating Principal Investigator~* Written Informed Consent is obtained~* Subject is willing to comply with study procedures and is able to return to the clinic for scheduled visits~Exclusion Criteria:~* Subject's HbA1C level is \> 9%.~* Subject is on insulin therapy~* Subject has history of recurrent hypoglycaemia~* Subject has history of malignancy (except skin cancer) during last 5 years~* Subject has received treatment for endocrinopathy within the last 3 months (except diabetes)~* Subject has history of adverse drug reaction to testosterone~* Subject has received testosterone replacement within the last 3 months~* Subject is currently receiving warfarin, steroids, cyclosporine or thyroxine~* Subject has history of Myocardial Infarction~* Subject has history of Angina~* Subject has heart failure which causes at least slight limitation of physical activity. Subject is comfortable at rest, but ordinary physical activity results in fatigue, palpitation or dyspnea~* Subject has history of Deep Vein Thrombosis or Stroke~* Subject has history of prostate cancer~* Subject has history of chronic kidney disease , Stage 3 or worse~* Subject has life expectancy of less than 1 year~* Subject has enlarged prostate per digital rectal examination~* Subject's International Prostate Symptom Score (IPSS) is greater than 20

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Oral Testosterone Therapy (Type: OTHER): 90 day oral testosterone therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues